The Journal of Urology
Volume 179, Issue 2 , Pages 408-413 , February 2008

The Role of Pelvic Lymphadenectomy for Prostate Cancer—Therapeutic?

  • M. Wagner
    • ,
  • M. Sokoloff
    • ,
  • S. Daneshmand

      Affiliations

    • Corresponding Author InformationCorrespondence: 3181 Southwest Sam Jackson Park Rd., Mail Code L588, Portland, Oregon 97239 (telephone: 503-494-8470; FAX: 503-494-8671).

Received 22 March 2007

References 

  1. Cunéo B, Marcille M. Note sur les lymphatiques de la vessie. Bull Mem Soc Anat. 1901;6:649
  2. Janoff DM, Parra RO. Contemporary appraisal of radical perineal prostatectomy. J Urol. 2005;173:1863
  3. Freiha FS, Salzman J. Surgical staging of prostatic cancer: transperitoneal versus extraperitoneal lymphadenectomy. J Urol. 1977;118:616
  4. Castellino RA, Ray G, Blank N, Govan D, Bagshaw M. Lymphangiography in prostatic carcinoma (Preliminary observations). JAMA. 1973;223:877
  5. Raghavaiah NV, Jordan WP. Prostatic lymphography. J Urol. 1979;121:178
  6. Fowler JE, Whitmore WF. The incidence and extent of pelvic lymph node metastases in apparently localized prostatic cancer. Cancer. 1981;47:2941
  7. McDowell GC, Johnson JW, Tenney DM, Johnson DE. Pelvic lymphadenectomy for staging clinically localized prostate cancer (Indications, complications, and results in 217 cases). Urology. 1990;35:476
  8. Schwartz KL, Severson RK, Gurney JG, Montie JE. Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973–1994. Cancer. 1996;78:1260
  9. Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol. 2004;172:1840
  10. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172:910
  11. Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup. J Urol. 2004;172:1860
  12. Gervasi LA, Mata J, Easley JD, Wilbanks JH, Seale-Hawkins C, Carlton CE, et al. Prognostic significance of lymph nodal metastases in prostate cancer. J Urol. 1989;142:332
  13. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7:472
  14. Clark T, Parekh DJ, Cookson MS, Chang SS, Smith ER, Wells N, et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol. 2003;169:145
  15. Briganti A, Chun FK, Salonia A, Suardi N, Gallina A, Da Pozzo LF, et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol. 2006;50:1006
  16. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol. 2002;167:1681
  17. Bigg SW, Catalona WJ. Prophylactic mini-dose heparin in patients undergoing radical retropubic prostatectomy (A prospective trial). Urology. 1992;39:309
  18. Soh S, Kattan MW, Berkman S, Wheeler TM, Scardino PT. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?. J Urol. 1997;157:2212
  19. Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer?. J Urol. 2002;168:514
  20. Wang L, Hricak H, Kattan MW, Schwartz LH, Eberhardt SC, Chen HN, et al. Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR Am J Roentgenol. 2006;186:743
  21. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med. 2003;44:331
  22. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer (A multi-institutional update). JAMA. 1997;277:1445
  23. Blute ML, Bergstralh EJ, Partin AW, Walsh PC, Kattan MW, Scardino PT, et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol. 2000;164:1591
  24. Bishoff JT, Reyes A, Thompson IM, Harris MJ, St Clair SR, Gomella L, et al. Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. Urology. 1995;45:270
  25. Meng MV, Carroll PR. When is pelvic lymph node dissection necessary before radical prostatectomy? (A decision analysis). J Urol. 2000;164:1235
  26. Kawakami J, Meng MV, Sadetsky N, Latini DM, Duchane J, Carroll PR, et al. Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE. J Urol. 2006;176:1382
  27. Masterson TA, Bianco FJ, Vickers AJ, DiBlasio CJ, Fearn PA, Rabbani F, et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol. 2006;175:1320
  28. Briganti A, Chun FK, Salonia A, Gallina A, Farina E, Da Pozzo LF, et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int. 2006;98:788
  29. Chun KF, Roman H, Heinzer H, Graefen M, Huland H, Briganti A, et al. Number of lymph nodes removed and examined and the continent of origin represent the foremost predictors of lymph node invasion in men with clinically localized prostate cancer. J Urol. 2007;175(suppl.):310;abstract 963
  30. Weckermann D, Dorn R, Trefz M, Wagner T, Wawroschek F, Harzmann R. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients. J Urol. 2007;177:916
  31. Studer UE. Editorial comment. J Urol. 2003;169:148
  32. Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy (Is there a chance of cure?). J Urol. 2003;169:849
  33. Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol. 2004;172:2252
  34. Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology. 2006;68:121
  35. Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein JP, et al. Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol. 2006;24:2735
  36. Bhatta-Dhar N, Reuther AM, Zippe C, Klein EA. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Urology. 2004;63:528
  37. DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol. 2005;173:1121
  38. Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol. 1999;161:1223

PII: S0022-5347(07)02498-6

doi: 10.1016/j.juro.2007.09.027

The Journal of Urology
Volume 179, Issue 2 , Pages 408-413 , February 2008

Article Tools

* Image Usage & Resolution